FDA committee back Geron’s blood disorder drug
The committee ultimately backed the benefits of imetelstat based on data from the Phase III IMerge clinical trial.
The committee ultimately backed the benefits of imetelstat based on data from the Phase III IMerge clinical trial.
What's Your Reaction?
